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Abstract
Because oxidative stress after administration of doxorubicin was identified as playing 
a central role in cardiac dysfunction, we hypothesized that the expression (or overex-
pression) of TLR2 and TLR4 contributes to the pathogenesis of doxorubicin-induced 
cardiac dysfunction. Toll-like receptors (TLRs) are members of the interleukin-1 receptor 
family (IL1) and are involved in the ability to react to the molecular trigger associated 
with pathogenic microorganisms. Recent studies have shown that TLR receptors are 
activated by endogenous signals, such as heat shock proteins and oxidative stress, which 
can contribute to congestive heart failure. Until recently, the best detection method for 
cardiotoxicity induced by anthracyclines was myocardial biopsy. Other early screening 
and early diagnosis methods (biomarkers—cardiac troponins and natriuretic peptide) 
have not yet proven their efficacy. Our proposed method is a new, revolutionary one 
that does not imply any kind of physical (and psychic) aggression on the patient: the 
targeted genetic (TLR2/TLR4) analysis of the human peripheral blood (which is a mini-
mally invasive procedure).
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1. Introduction
Immunotherapy for cancer has been and still is a subject of intense research since the nine-
teenth century when Coley noticed that bacterial components can contribute to cancer regres-
sion and can cause an immune antitumor immune response.
Permanent cardiotoxic effects of conventional cytostatic therapy underscore the need for early 
diagnostic methods with great sensitivity to allow early detection of signs of cardiac dysfunc-
tion, the consequence of the cardiotoxic effects of cytostatic medication. The specificity of any 
test should allow for a precise risk/benefit analysis, a balance between the probability of car-
diac dysfunction due to high drug doses and the consequences of stopping antitumor therapy.
Several Toll-like receptors (TLRs) are expressed in cardiomyocytes, including TLRs 2 and 4. 
Through these TLRs, cardiomyocytes respond to endogenous or exogenous signals that can 
influence pathophysiological responses to dilated cardiomyopathy. Expression or activation of 
both TLR2 and TLR4 are overregulated in experimental and in vivo (hypertensive and/or clinical 
heart failure patients) models. Therefore, inhibition of TLR signaling may be of great therapeutic 
benefit for dilatation cardiomyopathy (CMD), especially in the treatment with doxorubicin.
2. Serum markers: cardiac troponins and natriuretic peptide
For cardiovascular disorders, including doxorubicin-induced heart failure, an increased num-
ber of candidate markers were studied to be useful in detecting myocardial injuries. These 
include cardiac troponins and natriuretic peptides.
However, most of the results have highlighted the fact that some of the patients have detect-
able troponin, suggesting that this may be considered as a prognostic marker for doxorubicin-
induced cardiotoxicity.
Cardiac troponins are complex joints of thin filaments that are involved in the regulation of 
actin-myosin coupling in the cardiac muscle and consist of three subunits: troponins T, C, 
and I [1–4].
Cardiac troponins T and I are both highly sensitivity and have specificity for myocardial 
injuries [5]. Both markers are used as prognostic and diagnostic tools in acute coronary syn-
drome [6]. Cardiac troponins have also been studied from the perspective of use as markers 
for anthracycline-induced cardiotoxicity, with bivalent results [7].
These contradictory results can be determined by many factors, such as heterogeneous popu-
lation studies, variable cumulative doses of anthracycline, and different study protocols with 
different working methods.
The utility of troponins was mainly demonstrated after administration of antineoplastic 
and β-sympathomimetic drugs, although the routine use of these markers in monitoring in 
patients receiving anthracycline therapy is far from being solved.
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3. Toll-like receptor and cardiotoxicity
Toll-like receptors (TLRs) are members of the interleukin-1 receptor family (IL1) and are 
involved in the ability to react to the molecular trigger associated with pathogenic micro-
organisms. Recent studies have shown that TLRs are activated by endogenous signals, such 
as heat shock proteins and oxidative stress, which can contribute to congestive heart failure.
Oxidative stress is one of the major doxorubicin (Dox)-induced cardiac dysfunctions. Thus, 
we hypothesized that TLRs contribute to the pathogenesis of doxorubicin-induced cardiac 
dysfunction.
Toll-like receptors (TLRs) recognize pathogens associated with molecular patterns such as 
lipopolysaccharides, peptidoglycan, bacterial lipoproteins, and oligonucleotides during 
inflammatory response.
TLRs have interleukin-1 (IL1)-like response pathways as an intracellular signaling means lead-
ing to the nuclear localization of the kb/Rel-type nuclear transcription factor (NF). Moreover, 
TLRs are expressed in various organs, such as the lung, brain, kidneys, heart, etc.
Recent studies have suggested that the “activated myocardium” through mediated TLR sig-
naling pathways in response to exogenous ligands induces myocardial dysfunction.
Other studies analyzed by us for scientific documentation have also demonstrated that there 
are other signaling-mediated TLR pathways that are activated by endogenous signals such 
as heat shock protein and oxidative stress in cardiomyocytes isolated from ventricular level.
We must also keep in mind that it has recently been shown that TLR2 plays an important role 
in ventricular remodeling after myocardial infarction and also with cardiac specificity (TLR4 
compared to it does not have a system/organ specificity).
Doxorubicin (Dox) is an effective antitumor antibiotic in the anthracycline class. However, 
doxorubicin also induces cardiomyopathy leading to congestive heart failure, thus often lim-
iting its clinical use.
Doxorubicin-induced cardiomyopathy is mainly caused by increased cardiac oxidant 
production.
It has also been reported that treatment with doxorubicin causes the release of cytochrome C 
and results in the activation of caspase 3 and cellular apoptosis.
These studies also indicate that free radicals play an important role in doxorubicin-induced 
cardiotoxicity.
Because oxidative stress after administration of doxorubicin was identified as playing a cen-
tral role in cardiac dysfunction, we hypothesized that the expression (or overexpression) of 
TLR2 and TLR4 contributes to the pathogenesis of doxorubicin-induced cardiac dysfunction.
Successful activation and maturation of specific tumoral immune cells are known to be medi-
ated by bacterial endotoxin, which activates Toll-like receptor 4 (TLR4). TLR4 is expressed 
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on a variety of immune and tumor cell types, but its activation may have opposite effects. 
While activation of TLR4 may promote antitumor immunity, it can also cause excessive tumor 
growth and immunosuppression.
However, TLR4 binding to endotoxin, as well as endogenous ligands, is a notable contri-
bution to the outcome of treatment of various cancers, such as radiation or chemotherapy. 
Further research into the role and mechanisms of TLR4 activation in cancer may provide 
new antitumor adjuvants as well as TLR4 inhibitors that could prevent inflammation-induced 
carcinogenesis or the cardiotoxic effect of anthracyclines in treatment.
The immune system plays an important role not only in defending against microbial infection 
but also in controlling and monitoring malignant tumors.
Immune cells scan the tissues with the objective of eliminating newly formed malignant cells 
before transforming into fully formed tumors. Malignant cells develop complicated mecha-
nisms that allow them to inhibit immune cells by secreting specific cytokines that create an 
immunosuppressive medium [1]. Tumors can even directly kill the tumor-lymphocyte infil-
tration, which are CD95 sensitive, by expressing CD95L (Fas ligand) [2].
So, inborn immunity is the first line of defense against microbial infection. The innate immune 
system cells can recognize the pathogen, and the appropriate immune response is triggered 
by Toll-like receptors (TLRs), undoubtedly the most important sets of immune-derived 
vertebrate receptors. TLRs recognize different molecules of microbial origin, called associ-
ated pathogenic molecular models. TLRs are located on the cell surface (TLR1, 2, 4, 5, 6) or 
endosomal compartments (TLR3, 7, 8, 9) with the main role to protect the body from infec-
tion. After recognizing these ligands, the TLRs dimerize and trigger a cytoplasmic signaling 
pathway that leads to the activation of several nuclear factors (e.g., NFκB, IRF) responsible for 
transcription of immune system genes [3].
Signaling of TLR receptors in immune system cells is critical for regulating innate and adap-
tive immune response, such as for antigen maturation and presentation as well as for CD8 + 
and T-cell cytotoxicity, all of which are important factors in antitumor immunity [4]. On the 
other hand, TLR stimulation may also lead to the proliferation of improved T-cell regulatory 
and suppressor-like functions in tumor development [5–7].
TLR expression is not limited to immune cells, and indeed many tumor cells have been 
determined by expression of TLRs, signaling by which they can stimulate tumor growth and 
immune system evasion [8, 9]. On the other hand, TLR signaling in tumor cells has also been 
demonstrated to reduce the proliferative capacity of tumor cells [10]. We will focus on reports 
on TLR4 signaling and its involvement in cancer development and progression.
3.1. Toll-like receptor 4 in health and sickness
TLRs are Toll homologs, insect receptors, which are involved in the determination of dor-
soventral polarity during embryogenesis, as well as in the immune response against fungal 
infections [11, 12]. The first to be found in the human race was TLR4. Endotoxin (i.e., lipo-
polysaccharides), an external membrane component of Gram-negative bacteria, which is com-
posed of a preserved amphipathic lipid and other variable polysaccharides, is also recognized.
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The TLR4 activation mechanism is quite complex and (unlike other TLRs) involves several 
auxiliary proteins (LBP, CD14) and a coreceptor (MD-2) [3] (Figure 1). This is actually MD-2 
and not TLR4 that recognizes and binds directly to endotoxin [13, 14]. MD-2 is a soluble 
protein with a large hydrophobic pocket that represents the binding site for the lipid A lipid 
chains. Lipid A is usually composed of six acyl chains, but only five of them are bound in the 
hydrophobic pocket of MD-2.
The sixth acyl chain leaves the pocket and interacts with hydrophobic residues on the TLR4. 
These interactions are crucial for MD-2/TLR4 heterodimerization and are therefore a prereq-
uisite for TLR4 activation, a cascade signaling [15, 16].
3.1.1. Recommendations for the evaluation of cardiac biomarkers: BNP and cTnI
Recommended method: microparticle enzyme immunoassay (MEIA), quantitative deter-
mination of troponin I-cTnI in serum or plasma (troponin I cut-off value <0.04 ng/ml), and 
quantitative determination of BNP in plasma (BNP-100 pg/mL cut-off value).
Sample collection: from each patient, take 2 ml of fresh blood for each sample collected in 
plastic tubes; subsequently centrifuge and store plasma/serum samples under optimum con-
ditions at −20°C; and the maximum limit of 2 months is not exceeded.
The number of samples taken from each patient should be two, with a certain periodicity: ini-
tially (before initiation of treatment), after the first three cycles of doxorubicin-anthracyclines, 
and 3 months after initiation of treatment or from inclusion in study.
Figure 1. TLR4 spatial representation.
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3.1.2. Genetic study for TLR2 and TLR4
As previously mentioned, Toll-like receptors (TLRs) are members of the interleukin-1 recep-
tor family (IL1) and are involved in the ability to react to the molecular trigger associated with 
pathogenic microorganisms. Recent studies have shown that TLR receptors are activated by 
endogenous signals, such as heat shock proteins and oxidative stress, which can contribute to 
congestive heart failure.
Oxidative stress is one of the major doxorubicin (Dox)-induced cardiac dysfunctions. Thus, 
we hypothesized that TLR receptors contribute to the pathogenesis of doxorubicin-induced 
cardiac dysfunction.
Toll-like receptors (TLRs) recognize pathogens associated with molecular patterns such as 
lipopolysaccharides, peptidoglycan, bacterial lipoproteins, and oligonucleotides during 
inflammatory response.
TLRs have interleukin-1 (IL1)-like response pathways as an intracellular signaling means lead-
ing to the nuclear localization of the kb/Rel-type nuclear transcription factor (NF). Moreover, 
TLRs are expressed in various organs, such as the lung, brain, kidneys, heart, etc.
Recent studies have suggested that the “activated myocardium” through mediated TLR sig-
naling pathways in response to exogenous ligands induces myocardial dysfunction.
Other studies analyzed by us for scientific documentation have also demonstrated that there 
are other signaling-mediated TLR pathways that are activated by endogenous signals such 
as heat shock protein and oxidative stress in cardiomyocytes isolated from ventricular level.
We must also keep in mind that it has recently been shown that TLR2 plays an important role 
in ventricular remodeling after myocardial infarction and also with cardiac specificity (TLR4 
compared to it does not have a system/organ specificity).
Doxorubicin (Dox) is an effective antitumor antibiotic in the anthracycline class. However, 
doxorubicin also induces cardiomyopathy leading to congestive heart failure, thus often lim-
iting its clinical use.
Doxorubicin-induced cardiomyopathy is mainly caused by increased cardiac oxidant 
production.
It has also been reported that treatment with doxorubicin causes the release of cytochrome C 
and results in the activation of caspase 3 and cellular apoptosis.
These studies also indicate that free radicals play an important role in doxorubicin-induced 
cardiotoxicity.
Because oxidative stress after administration of doxorubicin was identified as playing a cen-
tral role in cardiac dysfunction, we hypothesized that the expression (or overexpression) of 
TLR2 and TLR4 contributes to the pathogenesis of doxorubicin-induced cardiac dysfunction.
3.1.3. TLR2 and TLR4 genetic study methods
For sampling we recommend the use of Tempus ™ Blood RNA Tube tubes (4,342,792, Applied 
Biosystems®—Figures 2–4).
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The tubes contain 6 ml Stabilizing Reagent.
Each tube will harvest 3 ml of peripheral venous blood from patients.
After harvest, the blood is mixed with the cell lysate stabilizing solution at the same time. The 
stabilizing agent inside the tube contains inhibitors of RNase while maintaining stable gene 
expression for more than 7 days at 4°C.
Figure 2. Tempus™ blood RNA tubes.
Figure 3. Graphic representation of the RNA isolation procedure.
New Biomarkers in Screening Anthracycline-Induced Cardiotoxicity Only with Peripheral Blood…
http://dx.doi.org/10.5772/intechopen.79587
145
The stabilizing solution allows the RNA to precipitate by maintaining the DNA and proteins 
in the solution.
After harvesting, samples should be kept at 4°C until RNA is isolated. Isolation of RNA will 
take place within 5 days of harvesting.
The RNA isolation procedure includes:
The contents of the Tempus ™ Blood RNA Tube tubes were transferred to 50 mL tubes.
3 mL of PBS will be added.
Stir for 30 seconds after which the samples are vortexed at 3000 g for 30 minutes.
After centrifugation, the supernatant is discarded, and the tube is left in place for 1–2 minutes 
on an absorbent material.
The RNA pellet is resuspended in 400 μL of Purification Resuspension Solution and vortexed 
briefly; after resuspension the RNA will be purified.
3.1.4. Obtaining complementary DNA (cDNA)
For the reverse transcription reaction, the High Capacity cDNA Reverse Transcription Kits 
(4,368,814, Applied Biosystems) kit will be used.
The procedure for obtaining cDNA is:
Two master RT mixes according to Table 1 will be prepared.
Use 10 μL of 2X RT and 10 μL of RNA for a reaction, to obtain the RNA solution; the RNA 
samples should be diluted so that in the final 100 ng/5 μL RNA solution 400 ng RNA will be 
used for a 20 μL reaction volume.
The amplification reaction will be performed using the 2720 Thermal Cycler (Applied 
Biosystems) according to the specified program (Table 2).
Figure 4. Graphic representation of the RNA isolation procedure.
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3.1.5. Determination of relative gene expression for TLR2 and TLR4 from isolated RNA 
samples
For qRT-PCR amplification, the LightCycler 480 SYBR Green I Master kit, which is optimized 
for the LightCycler 480 Thermocycler, is used. The GAPDH was chosen as the reference 
gene. The sequence of amplimers used for the experiments is shown in the following table 
(TLR2 and TLR4 expression in peripheral blood mononuclear cells of patients with chronic 
cystic echinococcosis and its relationship with IL-10, Parasite Immunology, 2011, 33, 692–696, 
J.-Y. Shan, W.-Z. JI, H.-T. LI, T. Tuxun, R.-Y. LIN1, & H. Wen) (Table 3).
Component Quantity (μL)
10✕ RT Buffer 2.0
25× dNTP Mix (100 mM) 0.8
10× RT Random Primers 2.0
MultiScribe™ Reverse Transcriptase 1.0
RNase Inhibitor 1.0
Nuclease-free H2O 3.2
Total volume/reaction 10.0
Table 1. Preparation of 2 × RT master mix with inhibitor/reaction RNase.
Step 1 Step 2 Step 3 Step 4
Temperature (°C) 25 37 85 4
Time (min) 10 120 5 ∞
Table 2. The reverse transcription program.
TLR 2 Sequence Bp Tm GC% Product 
length
Forward primer GGCATGTGCTGTGCTCTGTT 20 61.52 55.00 125
Reverse primer GCTTTCCTGGGCTTCCTTTT 20 58.66 50.00
TLR 4 Sequence Bp Tm GC% Product 
length
Forward primer TTGAGCAGGTCTAGGGTGATTGAAC 25 62.54 48.00 143
Reverse primer ATGCGGACACACACACTTTCAAATA 25 61.72 40.00
GAPDH Sequence Bp Tm GC% Product 
length
Forward primer GCACCGTCAAGGCTGAGAAC 20 61.57 60.00 138
Reverse primer TGGTGAAGACGCCAGTGGA 19 61.14 57.89
Table 3. The sequence of used  amplicons.
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Amplicons should be brought to a concentration of 10 μM and cDNA samples at a concentra-
tion of 25 ng/μl.
In a 0.5 mL Eppendorf tube, prepare the PCR mix according to Table 4.
From this mix, place 15 μl each well of the multiwell plate, and then add 5 μl cDNA to the 
appropriate wells. Seal the plate with heat-resistant foil, and centrifuge at 1500 g for 2 minutes. 
After centrifugation, the plate will be inserted into the LightCycler 480, and the amplification 
program presented and detailed in this chapter will be used.
After amplification we recommend that the data be analyzed with the LightCycler 480 
Software, Basic/Advanced Relative Quantitation (Table 5).
4. Explanations and discussion
A simple representation of the concept of a research (or knowledge) system in science and 
engineering can be imagined as a “black box,” considered only in terms of inputs, outputs, 
and function of the system or process in that system.
The current state of knowledge from the perspective of myocardial immunomodulation dur-
ing and after (possibly) cardiotoxic treatment with anthracycline (especially doxorubicin) can 
Components 1×
H2O 3 μl
Primer F 1 μl
Primer R 1 μl
SYBR Green Master 10 μl
Total 15 μl
Table 4. The PCR mix.
Activity Number of cycles Temp (°C) Duration Fluorescence acquisition
Preincubation 1 96 5 minutes —
Amplification 45 95 10 seconds —
60 10 seconds —
72 20 seconds Single
Melting analysis 1 95 5 seconds
1 55 1 minute
1 97 — Continuous
Cooling 1 40 10 seconds —
Table 5. Staged purification program.
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be empirically exemplified by this term “black box.” I mean, we own a “black box”; we know 
what goes into this “box”; we know as well what goes out DAR; we do not know what’s going 
on inside this “box.”
Thus, we know of the presence of an immunomodulating inflammatory process in response 
to the anthracycline/doxorubicin molecular response and reaction; we know “cardiotoxic 
cardiovascular remodeling,” but we do not know in detail the mechanisms by which these 
specific phenomena or specific immunological activators are responsible.
Dilated cardiomyopathy, a common cause of heart failure, is characterized by progressive 
cardiac remodeling and a decline in cardiac function. Currently, in the literature, the 5-year 
mortality rate for patients with dilatation cardiomyopathy is 50%. While many studies have 
documented that dilated cardiomyopathy has both idiopathic and genetic origins, it is being 
attempted at international academic medical level to demonstrate that inflammation of dif-
ferent origins and manifestations also induces dilated cardiomyopathy. Doxorubicin (Dox) is 
an effective antitumor agent. Despite its use as a common chemotherapeutic agent, the use of 
Dox may lead to cardiotoxicity.
Multiple intravenous treatments with doxorubicin over a period of several months have 
been shown to induce cardiomyopathy in mice and cardiomyopathy in humans [8]. Inborn 
immune response is the first line of defense and is responsible for the immediate recogni-
tion and counteraction of microbial invasion or any agents considered harmful to the body. 
This component of the immune system consists mainly of phagocytes-macrophages and 
neutrophils—which ingest and kill pathogens and then transmit information to the adaptive 
immune system by producing cytokines and chemokinesis by presenting to the lymphocytes 
the microbial antigen, which leads to the development of a specific response.
This specificity of the adaptive immune response, which is mediated by B and T lymphocytes, 
is accomplished by somatic mutations and the selection of receptors that most accurately rec-
ognize microbial antigens. In contrast, the innate immune response uses “pattern recognition 
receptors” (PRRs), which recognize highly conserved microbial structures, allowing the host 
to quickly identify a wide range of pathogens without the somatic mutation time. Generally, 
each receptor recognizes a series of microorganisms based on ligand specificities. Some 
receptors also have endogenous ligands and play essential roles in homeostasis (Brown G.D. 
2006). Key receptors involved in the recognition of infectious agents and products released by 
injured or “dying” cells are Toll-like receptors (TLRs).
Activation of innate immune system receptors is followed by rapid changes in gene expression, 
including genes for cytokines, chemokines, degradative enzymes, and enzymes responsible for 
the production of small molecule inflammatory mediators. Thus, the released cytokines and 
chemokines can activate and recruit other cells at the site of the infection or at the site of “the 
presence of a non-self” (in the case of doxorubicin both by direct effect on receptors and by 
synthesis and degreasing) finally leading to the activation of the adaptive immune response. 
In mammals, activation of TLR signaling induces both innate and adaptive immune responses. 
By phagocytosis of microbial pathogens or non-self agents, TLR membranes (TLR-2, TLR-4) 
are recruited by phagosomes and are thus activated (mature as self-contained components) 
through cellular or microbial wall components. This phagosome maturation is also regulated 
by intracellular signals transmitted by the TLR and ensures the selection of microbial antigens 
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and their presentation by MHC II molecules. It is imperative that immature innate responses 
be fine-tuned. Delayed or insufficiently comprehensive responses lead to a failure to control 
infection or overexpressed inflammatory response in our case (doxorubicin cure). However, 
excessive or inadequate inflammation may be harmful and even fatal. Hyperinflammatory 
responses that characterize the body’s response to treatment with doxorubicin or other 
anthracyclines provide a paradigmatic example, such as that excessive inflammation leads 
to inflammatory bowel disease and arthritis. Endogenous ligands of TLR2 and TLR4 include 
extracellular matrix products (hyaluronate and heparan sulfate) and molecules released by 
dead or injured cells (HMGB1, fibronectin, heat shock proteins, fibrinogen, and low density 
lipoproteins). Many of these molecules accumulate in patients’ joints or other inflammatory 
sites, for example, in the myocardium with subsequent expression through an inflammatory 
process. The precise mechanism by which the TLR recognizes such a wide range of struc-
tures is not yet clarified (Marshak-Rothstein A, 2006). Multiple Toll-like receptors (TLRs) 
are expressed in cardiomyocytes, including TLR2 and TLR4. By these TLRs, cardiomyocytes 
respond to endogenous or exogenous signals that may influence pathophysiological responses 
to induce dilated cardiomyopathy.
Expression or activation of both TLR2 and TLR4 is often expressed in experimental and 
research models (both human and animal) by hypertension and with proven clinical heart 
failure [6]. Therefore, inhibition of TLR signaling may be of great therapeutic benefit for doxo-
rubicin-induced cardiotoxic cardiomyopathy. Toll-like receptors (TLRs) recognize pathogens 
associated with molecular patterns such as lipopolysaccharides, peptidoglycan, bacterial lipo-
proteins, and oligonucleotides during inflammatory response. TLRs have interleukin-1 (IL1)-
like response pathways as an intracellular signaling means leading to the nuclear localization 
of the kb/Rel-type nuclear transcription factor (NF).
Moreover, TLRs are expressed in various organs, such as the lung, brain, kidneys, heart, etc. 
Recent studies have suggested that the “activated myocardium” through mediated TLR sig-
naling pathways in response to exogenous ligands induces myocardial dysfunction. Other 
studies analyzed by us for scientific documentation have also demonstrated that there are 
other signaling-mediated TLR pathways that are activated by endogenous signals such as 
heat shock protein and oxidative stress in cardiomyocytes isolated from ventricular level.
5. Conclusions
We must also keep in mind that it has recently been shown that TLR2 plays an important role 
in ventricular remodeling after myocardial infarction and also with cardiac specificity (TLR4 
compared to it does not have a system/organ specificity). Doxorubicin (Dox) is an effective 
antitumor antibiotic in the anthracycline class. However, doxorubicin also induces cardiomy-
opathy leading to congestive heart failure, thus often limiting its clinical use.
Doxorubicin-induced cardiomyopathy is mainly caused by increased cardiac oxidant produc-
tion. It has also been reported that treatment with doxorubicin causes the release of cytochrome 
C and results in the activation of caspase 3 and cellular apoptosis. These studies also indicate 
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that free radicals play an important role in doxorubicin-induced cardiotoxicity. Because oxi-
dative stress after administration of doxorubicin has been identified to play a central role in 
cardiac dysfunction, we hypothesized that the expression (or overexpression exact) of TLR2 
and TLR4 contributes to the pathogenesis of doxorubicin-induced cardiac dysfunction.
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